IPROPLATIN is a quadrivalent second-generation platinum complex. It binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and tumor cell death. IPROPLATIN was discontinued in phase III clinical trials.

Livoletide (AZP-531) is an analog of unacylated ghrelin, a naturally occurring hormone that is thought to counteract the effects of acylated ghrelin. The drug was designed to improve glycaemic control and reduce weight. Livoletide participated in pivotal phase 2b/3 clinical study for the treatment of Prader-Willi syndrome. In addition, the drug was studied in patients with type 2 diabetes mellitus (T2D). Its pharmacokinetic profile, suitable for once daily dosing, and metabolic effects support further clinical development for T2D.

Meseclazone (W-2395) is a non-steroidal anti-inflammatory drug. It exerts anti-inflammatory, analgesic and antipyretic activity. Meseclazone inhibits in vitro and ex vivo platelet aggregation initiated by the release reaction. It inhibits bradykinin-induced bronchospasm.

Inakalant is diazabicyclo[3.3.1]nonane derivative patented by pharmaceutical company AstraZeneca AB as antiarrhythmic agent.

Deloxolone was devoid of aldosterone-like properties. Deloxolone could be of therapeutic value in peptic ulcer diseases without inducing fluid retention, hypertension and hypokaliemia. Carbenoxolone and deloxolone were orally administered to healthy volunteers in a cross-over double-blind trial. Both the concentration in gastric juice and the output of PGE2, determined by an RIA method in basal conditions and after pentagastrin bolus, increased in drug-treated compared to vehicle-treated subjects thus supporting the hypothesis that cytoprotection might be due to gastric PGE, levels. Moreover, deloxolone induced less marked effects than carbenoxolone on body weight, hematocrit, plasma potassium and proteins, confirming that deloxolone is less similar to aldosterone than the reference drug.

ITROCINONIDE is a synthetic corticosteroid which showed no signs of systemic activity (cortisol depression).

Pleuromulin (pleuromulitin) is a natural antibiotic isolated from Basidiomycete Pleurotus. Pleuromulitin exhibits activity mainly against gram-positive bacteria including S. aureus, Klebasiella pneumoniae and Bacillus Subtilis. Pleuromulin is an organic compound which is not reported to be used in as a drug however its derivatives have been used in treatment of infections. The first pleuromulitin that was approved in 1979 for use in veterinary medicine was semi-synthetic derivative tiamulin. Semisynthetic pleuromutilin retapamulin (ALTABAX, GlaxoSmithKline) was the first approved for topical use in humans in 2007. Another derivative of pleuromulin, Lefamulin has been successfully tested in phase 1 clinical trial for systemic use in patients (Nabriva Therapeutics AG).